ClinicalTrials.gg
CompletedNCT03615066Updated May 10, 2022Results posted

Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment

A Phase 2 interventional study of Placebo and Selgantolimod in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 10 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-05-10.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Hepatitis B, Chronic by Gilead Sciences — none open to participants now, 2 under way, 1 of them phase 3. Hepatitis B, Chronic · Gilead Sciences.

Enrollment
22nd of 29
67 · median 112
Started
2018
with 2 others
Phase 2
15 of 34
none open now
Registered
32nd of 34
by date

Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 22nd largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2018, is one of 15 in phase 2, and was the 32nd registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 34 studies in Hepatitis B, Chronic by Gilead Sciences is open now. The open studies under Hepatitis B, Chronic, anywhere →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies in Hepatitis B, Chronic by Gilead Sciences as a file.
02

Study summary

The primary objectives of this study are to evaluate the safety and tolerability of multiple oral doses of selgantolimod and to evaluate the antiviral activity of selgantolimod in adult participants with chronic hepatitis B (CHB) who are viremic and not currently being treated.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have the ability to understand and sign a written form, which must be obtained prior to initiation of study procedures.
  • Adult male and non-pregnant, non-lactating females
  • Documented evidence of chronic virus (HBV) infection with detectable hepatitis B surface antigen (HBsAg) levels at screening
  • Screening HBV deoxyribonucleic acid (DNA) ≥ 2000 international units per milliliter (IU/mL).
  • Screening (ECG) without abnormalities

Key Exclusion Criteria:

  • Extensive bridging fibrosis or cirrhosis
  • Received a commercially available HBV OAV treatment(s) within the 3 months prior to screening.
  • Received prolonged therapy with immunomodulators or biologics within 3 months of screening
  • Individuals meeting any of the following laboratory parameters at screening:

    • > 5 * (ULN)
    • > ULN unless the individual is stable on an anticoagulant regimen
    • Albumin \< 3.5 g/dL
    • Direct >1.5x ULN
    • Count \< 100,000/µL
    • Estimated \< 60 mL/min (using the Cockcroft-Gault method)
  • Co-infection with (HIV), virus or hepatitis D virus
  • Prior history of hepatocellular carcinoma or screening alpha-fetoprotein ≥ 50 ng/mL without imaging
  • Diagnosis of disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe , hemoglobinopathy, retinal disease, or are .
  • Chronic liver disease of a non-HBV etiology except for non-alcoholic fatty liver disease.
  • Received solid organ or bone marrow transplant.
  • Use of another agent within 90 days of screening, unless allowed by the sponsor.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Selgantolimod 3 mg + TAF

    Participants with Hepatitis B e antigen (HBeAg)-positive CHB or HBeAg-negative CHB currently not on oral antiviral (OAV) treatment, will receive selgantolimod 3 mg (2 x 1.5 mg tablet) on the same day once weekly for 24 doses along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.

    Drug: Selgantolimod · Drug: TAF

  • Experimental
    Selgantolimod 1.5 mg + TAF

    Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) and placebo (1 tablet) on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.

    Drug: Placebo · Drug: Selgantolimod · Drug: TAF

  • Placebo comparator
    Placebo + TAF

    Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive 2 tablets of placebo on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, placebo will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.

    Drug: Placebo · Drug: TAF

Interventions

  • DrugPlacebo

    Tablet(s) administered orally every 7 days for 24 doses in fasted state

  • Tablet(s) administered orally every 7 days for 24 doses in fasted state

    Also known as: GS-9688

  • DrugTenofovir alafenamideStudies of Tenofovir alafenamideTenofovir alafenamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tablet(s) administered orally once daily with food

    Also known as: Vemlidy®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24

    Time frame: Baseline, Week 24

  2. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE was any unfavorable and unintended sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the investigational medicinal product. A TEAE was defined as any AE with an onset date on or after the first dose date and no later than 30 days after permanent discontinuation of selgantolimod/placebo; or any AE leading to premature discontinuation of study drugs.

    Time frame: First dose date up to Week 24 plus 30 days

  3. Percentage of Participants With Treatment-Emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of the last dose of study drug plus 30 days for selgantolimod/placebo at Week 24. If the relevant baseline laboratory value was missing, any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment emergent. Clinical laboratory results were graded according to Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities.

    Time frame: First dose date up to Week 24 plus 30 days

Secondary outcomes

  1. Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4

    Time frame: Baseline, Week 4

  2. Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8

    Time frame: Baseline, Week 8

  3. Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12

    Time frame: Baseline, Week 12

  4. Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48

    Time frame: Baseline, Week 48

  5. Change From Baseline in Serum qHBsAg at Week 4

    Time frame: Baseline, Week 4

  6. Change From Baseline in Serum qHBsAg at Week 8

    Time frame: Baseline, Week 8

  7. Change From Baseline in Serum qHBsAg at Week 12

    Time frame: Baseline, Week 12

  8. Change From Baseline in Serum qHBsAg at Week 24

    Time frame: Baseline, Week 24

  9. Change From Baseline in Serum qHBsAg at Week 48

    Time frame: Baseline, Week 48

  10. Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < Lower Limit of Quantification (LLOQ) at Week 12

    LLOQ was defined as 20 IU/mL.

    Time frame: Week 12

  11. Percentage of Participants With HBV DNA < LLOQ at Week 24

    LLOQ was defined as 20 IU/mL.

    Time frame: Week 24

  12. Percentage of Participants With HBV DNA < LLOQ at Week 48

    LLOQ was defined as 20 IU/mL.

    Time frame: Week 48

  13. Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12

    HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

    Time frame: Week 12

  14. Percentage of Participants With HBsAg Loss at Week 24

    HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

    Time frame: Week 24

  15. Percentage of Participants With HBsAg Loss at Week 48

    HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

    Time frame: Week 48

  16. Percentage of Participants With HBeAg Loss and Seroconversion at Week 12

    HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as Hepatitis B e antibody (HBeAb) loss and anti-HBe change from negative/missing at baseline to positive at a postbaseline visit.

    Time frame: Week 12

  17. Percentage of Participants With HBeAg Loss and Seroconversion at Week 24

    HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb loss and anti-HBe change from negative/missing at baseline to positive at a postbaseline visit.

    Time frame: Week 24

  18. Percentage of Participants With HBeAg Loss and Seroconversion at Week 48

    HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.

    Time frame: Week 48

  19. Percentage of Participants With Virologic Breakthrough From Baseline up to Week 24

    Virologic breakthrough was defined as confirmed HBV DNA ≥ 69 IU/mL after having been \< 69 IU/mL or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir.

    Time frame: Baseline up to Week 24

  20. Percentage of Participants With Virologic Breakthrough From Baseline up to Week 48

    Virologic breakthrough was defined as confirmed HBV DNA ≥ 69 IU/mL after having been \< 69 IU/mL or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir.

    Time frame: Baseline up to Week 48

  21. Percentage of Participants With Drug Resistance Mutations

    Time frame: Baseline up to Week 48

  22. Pharmacokinetic (PK) Parameter: AUClast of Selgantolimod

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23

  23. PK Parameter: AUC0-24 of Selgantolimod

    AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23

  24. PK Parameter: AUCinf of Selgantolimod

    AUC0-inf is defined as the concentration of drug over time from time zero to infinity.

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23

  25. PK Parameter: Cmax of Selgantolimod

    Cmax is defined as the maximum concentration of drug.

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23

  26. PK Parameter: Tmax of Selgantolimod

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23

  27. PK Parameter: CL/F of Selgantolimod

    CL/F is defined as the apparent oral clearance following administration of the drug.

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23

  28. PK Parameter: t1/2 of Selgantolimod

    t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23

07

Results

Posted Jan 6, 2021

Participant flow

Participants were enrolled at study sites in Canada, South Korea, and Taiwan. The first participant was screened on 28 August 2018. The last study visit occurred on 12 April 2021.

Main Study
Participant flow — Main Study
MilestoneSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Started262813
Completed262711
Not completed012
Withdrew: Withdrew consent011
Withdrew: Lost to follow-up001
Treatment-free Follow-up (TFFU) Phase
Participant flow — Treatment-free Follow-up (TFFU) Phase
MilestoneSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Started13122
Completed11112
Not completed210
Withdrew: Adverse event100
Withdrew: Protocol violation100
Withdrew: Withdrew consent010

Outcome measures

PrimaryPercentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24
Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24000
PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE was any unfavorable and unintended sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the investigational medicinal product. A TEAE was defined as any AE with an onset date on or after the first dose date and no later than 30 days after permanent discontinuation of selgantolimod/placebo; or any AE leading to premature discontinuation of study drugs.

Time frame:
First dose date up to Week 24 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)84.660.776.9
PrimaryPercentage of Participants With Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of the last dose of study drug plus 30 days for selgantolimod/placebo at Week 24. If the relevant baseline laboratory value was missing, any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment emergent. Clinical laboratory results were graded according to Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities.

Time frame:
First dose date up to Week 24 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Laboratory Abnormalities
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With Treatment-Emergent Laboratory Abnormalities84.692.992.3
SecondaryPercentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4
Time frame:
Baseline, Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4000
SecondaryPercentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8
Time frame:
Baseline, Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8000
SecondaryPercentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12
Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12000
SecondaryPercentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48
Time frame:
Baseline, Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48000
SecondaryChange From Baseline in Serum qHBsAg at Week 4
Time frame:
Baseline, Week 4
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum qHBsAg at Week 4
log10 IU/mLSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Change From Baseline in Serum qHBsAg at Week 4-0.04 ± 0.155-0.01 ± 0.081-0.02 ± 0.065
SecondaryChange From Baseline in Serum qHBsAg at Week 8
Time frame:
Baseline, Week 8
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum qHBsAg at Week 8
log10 IU/mLSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Change From Baseline in Serum qHBsAg at Week 8-0.04 ± 0.161-0.05 ± 0.1210.00 ± 0.081
SecondaryChange From Baseline in Serum qHBsAg at Week 12
Time frame:
Baseline, Week 12
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum qHBsAg at Week 12
log10 IU/mLSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Change From Baseline in Serum qHBsAg at Week 12-0.04 ± 0.163-0.05 ± 0.1080.01 ± 0.099
SecondaryChange From Baseline in Serum qHBsAg at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum qHBsAg at Week 24
log10 IU/mLSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Change From Baseline in Serum qHBsAg at Week 24-0.08 ± 0.198-0.11 ± 0.174-0.03 ± 0.146
SecondaryChange From Baseline in Serum qHBsAg at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum qHBsAg at Week 48
log10 IU/mLSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Change From Baseline in Serum qHBsAg at Week 48-0.12 ± 0.218-0.16 ± 0.235-0.12 ± 0.145
SecondaryPercentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < Lower Limit of Quantification (LLOQ) at Week 12

LLOQ was defined as 20 IU/mL.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < Lower Limit of Quantification (LLOQ) at Week 12
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < Lower Limit of Quantification (LLOQ) at Week 1220.828.625.0
SecondaryPercentage of Participants With HBV DNA < LLOQ at Week 24

LLOQ was defined as 20 IU/mL.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < LLOQ at Week 24
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With HBV DNA < LLOQ at Week 2437.532.133.3
SecondaryPercentage of Participants With HBV DNA < LLOQ at Week 48

LLOQ was defined as 20 IU/mL.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < LLOQ at Week 48
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With HBV DNA < LLOQ at Week 4850.044.445.5
SecondaryPercentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12

HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12000
SecondaryPercentage of Participants With HBsAg Loss at Week 24

HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Week 24
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With HBsAg Loss at Week 24000
SecondaryPercentage of Participants With HBsAg Loss at Week 48

HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Week 48
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With HBsAg Loss at Week 48000
SecondaryPercentage of Participants With HBeAg Loss and Seroconversion at Week 12

HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as Hepatitis B e antibody (HBeAb) loss and anti-HBe change from negative/missing at baseline to positive at a postbaseline visit.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss and Seroconversion at Week 12
percentage of participantsSelgantolimod 3 mg + TAF: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg + TAF: HBeAg-positive CHB ParticipantsPlacebo + TAF: HBeAg-positive CHB Participants
HBeAg Loss000
SecondaryPercentage of Participants With HBeAg Loss and Seroconversion at Week 24

HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb loss and anti-HBe change from negative/missing at baseline to positive at a postbaseline visit.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss and Seroconversion at Week 24
percentage of participantsSelgantolimod 3 mg + TAF: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg + TAF: HBeAg-positive CHB ParticipantsPlacebo + TAF: HBeAg-positive CHB Participants
HBeAg Loss000
SecondaryPercentage of Participants With HBeAg Loss and Seroconversion at Week 48

HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss and Seroconversion at Week 48
percentage of participantsSelgantolimod 3 mg + TAF: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg + TAF: HBeAg-positive CHB ParticipantsPlacebo + TAF: HBeAg-positive CHB Participants
HBeAg Loss000
SecondaryPercentage of Participants With Virologic Breakthrough From Baseline up to Week 24

Virologic breakthrough was defined as confirmed HBV DNA ≥ 69 IU/mL after having been \< 69 IU/mL or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir.

Time frame:
Baseline up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Breakthrough From Baseline up to Week 24
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With Virologic Breakthrough From Baseline up to Week 243.87.115.4
SecondaryPercentage of Participants With Virologic Breakthrough From Baseline up to Week 48

Virologic breakthrough was defined as confirmed HBV DNA ≥ 69 IU/mL after having been \< 69 IU/mL or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir.

Time frame:
Baseline up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Breakthrough From Baseline up to Week 48
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With Virologic Breakthrough From Baseline up to Week 483.810.715.4
SecondaryPercentage of Participants With Drug Resistance Mutations
Time frame:
Baseline up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Drug Resistance Mutations
percentage of participantsSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Percentage of Participants With Drug Resistance Mutations000
SecondaryPharmacokinetic (PK) Parameter: AUClast of Selgantolimod

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
Reported as:
Mean · hr*pg/mL
Pharmacokinetic (PK) Parameter: AUClast of Selgantolimod
hr*pg/mLSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAF
Day 11163.0 ± 833.27548.0 ± 393.00
Week 231441.8 ± 1601.19491.2 ± 489.29
SecondaryPK Parameter: AUC0-24 of Selgantolimod

AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
Reported as:
Mean · hr*pg/mL
PK Parameter: AUC0-24 of Selgantolimod
hr*pg/mLSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAF
Day 11162.2 ± 832.29547.7 ± 392.77
Week 231440.5 ± 1598.05494.4 ± 485.56
SecondaryPK Parameter: AUCinf of Selgantolimod

AUC0-inf is defined as the concentration of drug over time from time zero to infinity.

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
Reported as:
Mean · hr*pg/mL
PK Parameter: AUCinf of Selgantolimod
hr*pg/mLSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAF
Day 11184.2 ± 843.53556.4 ± 394.38
Week 231462.8 ± 1616.70503.2 ± 492.66
SecondaryPK Parameter: Cmax of Selgantolimod

Cmax is defined as the maximum concentration of drug.

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
Reported as:
Mean · pg/mL
PK Parameter: Cmax of Selgantolimod
pg/mLSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAF
Day 1373.3 ± 208.63307.7 ± 311.12
Week 23591.0 ± 565.11268.2 ± 254.16
SecondaryPK Parameter: Tmax of Selgantolimod

Tmax is defined as the time (observed time point) of Cmax.

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
Reported as:
Median · hours
PK Parameter: Tmax of Selgantolimod
hoursSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAF
Day 10.98 (0.50 to 4.10)0.53 (0.28 to 1.80)
Week 230.55 (0.28 to 1.10)0.50 (0.28 to 0.55)
SecondaryPK Parameter: CL/F of Selgantolimod

CL/F is defined as the apparent oral clearance following administration of the drug.

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
Reported as:
Mean · mL/hr
PK Parameter: CL/F of Selgantolimod
mL/hrSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAF
Day 14094330.4 ± 3034917.794603039.8 ± 3733427.89
Week 234550308.6 ± 3858788.246223868.1 ± 5265428.49
SecondaryPK Parameter: t1/2 of Selgantolimod

t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
Reported as:
Median · hours
PK Parameter: t1/2 of Selgantolimod
hoursSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAF
Day 14.55 (4.32 to 4.95)5.13 (4.29 to 5.47)
Week 234.78 (3.95 to 4.95)5.03 (4.76 to 5.10)

Adverse events

Collected over All-Cause Mortality: Enrollment up to Week 96 Adverse Events: First dose up to last dose of selgantolimod/placebo (Week 24) plus 30 days; or TAF (Week 48) plus 3 days, whichever came later. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selgantolimod 3 mg + TAF0/26 (0%)1/26 (3.8%)21/26 (80.8%)
Selgantolimod 1.5 mg + TAF0/28 (0%)0/28 (0%)15/28 (53.6%)
Placebo + TAF0/13 (0%)0/13 (0%)10/13 (76.9%)
Most frequent serious events
Most frequent serious events
EventSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
Limb injuryInjury, poisoning and procedural complications1/260/280/13
Most frequent other events
Showing 10 of 55
Most frequent other events
EventSelgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAF
NauseaGastrointestinal disorders8/266/280/13
VomitingGastrointestinal disorders6/263/280/13
Upper respiratory tract infectionInfections and infestations2/261/283/13
FatigueGeneral disorders5/263/280/13
DizzinessNervous system disorders5/261/280/13
HeadacheNervous system disorders3/265/282/13
DiarrhoeaGastrointestinal disorders3/261/282/13
ChillsGeneral disorders4/260/280/13
PalpitationsCardiac disorders3/260/281/13
PruritusSkin and subcutaneous tissue disorders3/260/280/13

Baseline characteristics

The Safety Analysis Set included all participants who took at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)Selgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAFTotal
Mean46 ± 10.344 ± 12.146 ± 12.045 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Selgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAFTotal
Female1113428
Male1515939
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAFTotal
Hispanic or Latino0101
Not Hispanic or Latino26271366
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAFTotal
American Indian or Alaska Native0000
Asian25281366
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Selgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAFTotal
Canada1215633
South Korea710118
Taiwan73616
HBsAg
HBsAg(log10 IU/mL)Selgantolimod 3 mg + TAFSelgantolimod 1.5 mg + TAFPlacebo + TAFTotal
Mean3.8 ± 0.864.2 ± 0.834.0 ± 0.734.0 ± 0.82
08

Study locations

10 sites
  • University of Calgary Liver Unit - Heritage Medical Research Clinic
    Calgary, Alberta T2N4Z6, Canada
  • University Health Network, Toronto General Hospital, Toronto Centre for Liver Disease
    Toronto, Ontario M5G 2C4, Canada
  • Toronto Liver Centre
    Toronto, Ontario M6H 3M1, Canada
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Chung-Ang University Hospital
    Seoul, 06973, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 120-752, Korea, Republic of
  • E-Da Hospital
    Kaohsiung City, 82445, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, 807, Taiwan
  • National Taiwan University Hospital
    Taipei City, 10002, Taiwan
09

References and documents

Publications

  • Chen D, Kim S, Brooks A, McDonald C, Yang J, Gaggar A, et al. Potential Biomarkers of Response in Chronic Hepatitis B Patients Who Achieved HBeAg Loss Upon Treatment With Toll-Like Receptor 8 Agonist Selgantolimod [Poster]. The Digital International Liver Conference 2020 27-29 August.
  • Janssen H, Lampertico P, Chen C-Y, Heo J, Foumier C, Ahn S, et al. Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Renal Impairment: Week-48 Results From a Phase 2 Open-label Study [Poster]. The Digital International Liver Conference 2020 27-29 August.
  • Janssen H, Lim Y-S, Kim HJ, Tseng C-H, Coffin C, Elkashab M, et al. Safety and Efficacy of Oral TLR8 Agonist Selgantolimod in Viremic Adult Patients With Chronic Hepatitis B [Poster]. International Liver Congress 2021 23-26 June.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Dec 2019, 15 months.

Results were first posted in Jan 2021, 1 year after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 15 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2018
First posted
Aug 3, 2018
StartActual
Aug 28, 2018
Primary completionActual
Dec 12, 2019
CompletionActual
Apr 12, 2021
Results first posted
Jan 6, 2021
Last update
May 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03615066
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 3, 2018
Start date
Aug 28, 2018
Primary completion
Dec 12, 2019
Completion
Apr 12, 2021
Results posted
Jan 6, 2021
Last update
May 10, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selgantolimod

Start the discussion